LYRA - Lyra Therapeutics appoints Nieman as Chief Medical Officer
- Lyra Therapeutics ( NASDAQ: LYRA ) has appointed Dr. Richard Nieman as Chief Medical Officer, effective July 11, 2022.
- The industry leader with substantial U.S. and global experience in drug development and medical affairs joins Lyra as the company's late-stage product candidates advance in the clinic.
- Dr. Nieman assumes the role of Chief Medical Officer, previously held by Dr. Robert Kern, who will continue to work closely with the company in the role of Chief Clinical Advisor.
- The firm has approved the issuance of an equity-based award pursuant to its 2022 Inducement Award Plan to Dr. Nieman upon the commencement of his employment.
- The inducement grant consists of a non-qualified stock option to purchase an aggregate of 230,000 shares of the company's common stock.
For further details see:
Lyra Therapeutics appoints Nieman as Chief Medical Officer